Invesco Biotechnology & Genome ETF (PBE)

Invesco Biotechnology & Genome ETF (PBE) Financial Services Profile

Invesco Biotechnology & Genome ETF (PBE) seeks capital appreciation by investing in a portfolio of approximately 30 U.S. biotechnology and genome companies, tracking the Dynamic Biotech & Genome Intellidex Index, which uses investment merit criteria like price and earnings momentum, quality, management action, and value.

What Is the Investment Thesis for PBE?

The Invesco Biotechnology & Genome ETF (PBE), with a market capitalization of $258.33M and a beta of 1.07, presents a targeted investment vehicle for exposure to the biotechnology and genome sectors. The fund's strategy of tracking the Dynamic Biotech & Genome Intellidex Index, which selects companies based on factors like price and earnings momentum, aims to capture capital appreciation. The quarterly rebalancing schedule ensures the portfolio remains aligned with current market conditions. A key consideration is the absence of dividend yield, making it less attractive for income-focused investors. Growth is tied to the performance of the underlying biotechnology and genome companies, influenced by factors such as regulatory approvals, clinical trial outcomes, and technological advancements. Investors should monitor the performance of the index and the overall health of the biotechnology and genome industries.

Based on FMP financials and quantitative analysis

PBE Key Highlights

• Market Cap of $258.33M indicates a mid-sized ETF within the biotechnology and genome sector.
• Beta of 1.07 suggests the ETF's price is slightly more volatile than the overall market.
• The ETF invests at least 90% of its assets in securities comprising the Dynamic Biotech & Genome Intellidex Index.
• Quarterly rebalancing in February, May, August, and November ensures the portfolio remains aligned with the index's criteria.
• Absence of dividend yield may make it less attractive for income-focused investors.

Who Are PBE's Competitors?

PBE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PBE's Key Strengths?

• Exposure to high-growth biotechnology and genome sectors.
• Diversification across multiple companies reduces risk.
• Transparent index-tracking strategy.
• Quarterly rebalancing ensures portfolio alignment.

What Are PBE's Weaknesses?

• Subject to volatility in the biotechnology and genome sectors.
• Absence of dividend yield may deter income-focused investors.
• Performance is dependent on the success of the underlying companies.
• Expense ratio reduces overall returns.

What Could Drive PBE Stock Higher?

• Continuous advancements in biotechnology and genetic engineering driving innovation.
• Quarterly rebalancing in May 2026 to adjust portfolio based on index criteria.
• Growing demand for personalized medicine and targeted therapies.

What Are the Key Risks for PBE?

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory setbacks and clinical trial failures impacting portfolio companies.
• Market volatility and economic downturns affecting investor sentiment.
• Patent expirations and competition from generic drugs.
• Dependence on the performance of underlying biotechnology and genome companies.

What Are the Growth Opportunities for PBE?

• Increased Investment in Biotechnology Research and Development: Global investment in biotechnology R&D is projected to continue its upward trajectory, fueled by the demand for innovative therapies and diagnostics. This trend presents a significant growth opportunity for companies within the PBE portfolio. As these companies secure funding and advance their pipelines, their stock prices could appreciate, driving up the ETF's overall value. The timeline for realizing this growth is ongoing, with continuous advancements and breakthroughs expected in the coming years. The ETF benefits from diversification across multiple companies, mitigating the risk associated with individual company performance.
• Advancements in Gene Editing Technologies: The rapid development and application of gene editing technologies, such as CRISPR-Cas9, are revolutionizing the treatment of genetic diseases. Companies at the forefront of this field have the potential to generate substantial revenue through licensing agreements, partnerships, and the development of novel therapies. This growth opportunity is expected to unfold over the next 5-10 years as gene editing technologies mature and gain wider acceptance. PBE's exposure to companies involved in gene editing positions it to benefit from this transformative trend.
• Growing Demand for Personalized Medicine: The shift towards personalized medicine, where treatments are tailored to an individual's genetic makeup, is creating new opportunities for biotechnology companies. Diagnostic tests and targeted therapies are becoming increasingly important in healthcare, driving demand for companies specializing in these areas. This trend is expected to accelerate over the next decade as personalized medicine becomes more integrated into clinical practice. PBE's focus on biotechnology and genome companies aligns it with this growing demand, potentially leading to increased returns for investors.
• Aging Population and Increased Healthcare Spending: The global population is aging, leading to a greater prevalence of age-related diseases and increased healthcare spending. This demographic shift is creating a favorable environment for biotechnology companies that develop treatments for conditions such as cancer, Alzheimer's disease, and cardiovascular disease. The demand for these therapies is expected to rise steadily in the coming years, providing a long-term growth opportunity for PBE. The ETF's diversified portfolio helps to capture the potential upside from multiple companies addressing these healthcare needs.
• Expansion into Emerging Markets: Emerging markets are experiencing rapid economic growth and increasing access to healthcare, creating new opportunities for biotechnology companies. As these markets adopt advanced medical technologies and treatments, the demand for biotechnology products and services is expected to rise. Companies within the PBE portfolio that successfully expand into emerging markets could experience significant revenue growth. This growth opportunity is expected to unfold over the next 5-10 years as emerging markets continue to develop their healthcare infrastructure.

What Opportunities Does PBE Have?

• Increased investment in biotechnology R&D.
• Advancements in gene editing technologies.
• Growing demand for personalized medicine.
• Expansion into emerging markets.

What Threats Does PBE Face?

• Regulatory hurdles and clinical trial risks.
• Patent expirations and competition from generic drugs.
• Economic downturns and market volatility.
• Changes in healthcare policy and reimbursement rates.

What Are PBE's Competitive Advantages?

• Index-tracking strategy provides a defined and transparent investment approach.
• Diversification across multiple biotechnology and genome companies reduces risk.
• Established brand and reputation of Invesco as an asset manager.
• Quarterly rebalancing ensures the portfolio remains aligned with the index's criteria.

What Does PBE Do?

The Invesco Biotechnology & Genome ETF (PBE) is designed to provide investors with exposure to the biotechnology and genome sectors. Launched by Invesco, a well-established asset management firm, the fund operates by tracking the Dynamic Biotech & Genome Intellidex Index. This index focuses on U.S.-based companies that are principally engaged in the research, development, manufacture, and marketing of biotechnological products, services, and processes, as well as companies that benefit significantly from advances in biotechnology and genetic engineering. The ETF invests at least 90% of its total assets in the securities that comprise the Index. The Index employs a quantitative methodology, evaluating companies based on factors such as price momentum, earnings momentum, quality, management action, and value to identify those with the greatest potential for capital appreciation. The fund is rebalanced and reconstituted quarterly in February, May, August, and November, ensuring that the portfolio remains aligned with the index's criteria and reflects the latest market dynamics. PBE offers investors a way to gain diversified exposure to the biotechnology and genome sectors without having to individually select stocks, making it a convenient option for those seeking to participate in the growth of these industries.

What Products and Services Does PBE Offer?

• Invests in U.S. biotechnology and genome companies.
• Tracks the Dynamic Biotech & Genome Intellidex Index.
• Provides capital appreciation through investments.
• Rebalances and reconstitutes its portfolio quarterly.
• Focuses on companies engaged in biotechnology research, development, and manufacturing.
• Targets companies benefiting from advances in genetic engineering.

How Does PBE Make Money?

• Generates revenue through management fees charged to investors.
• Aims to outperform its benchmark index, the Dynamic Biotech & Genome Intellidex Index.
• Attracts investors seeking exposure to the biotechnology and genome sectors.
• Rebalances portfolio quarterly to maintain alignment with the index.

What Industry Does PBE Operate In?

The Invesco Biotechnology & Genome ETF (PBE) operates within the asset management industry, specifically focusing on the biotechnology and genome sectors. These sectors are characterized by high growth potential driven by advancements in genetic engineering, personalized medicine, and biopharmaceuticals. The competitive landscape includes other specialized ETFs and mutual funds that target similar segments of the market. The biotechnology industry is subject to regulatory scrutiny, clinical trial risks, and patent expirations, all of which can impact the performance of companies within the sector. PBE offers a diversified approach to investing in this dynamic and rapidly evolving industry.

Who Are PBE's Key Customers?

• Individual investors seeking exposure to the biotechnology and genome sectors.
• Institutional investors looking for diversified investment options.
• Financial advisors seeking to build portfolios for their clients.
• Retirement funds and pension plans.

PBE Valuation & Market Position

Relative to its peer group, PBE's quantitative score of 47/100 is roughly in line with the peer average of 48/100.

F-Score 3/9Financial Health

Invesco Biotechnology & Genome ETF's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.73 places it in the safe zone, indicating low near-term bankruptcy risk.

PBE Financials

PBE Latest News

PBE Analyst Consensus

PBE MoonshotScore

What Investors Ask About Invesco Biotechnology & Genome ETF (PBE) — Financial Services

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources